New Health Risks Emerge as Europe’s Drug Market Grows More Complex, EU Agency Warns
Poinews.com – New health risks emerge as Europe’s drug market becomes increasingly complex, prompting urgent warnings from the European Union Drugs Agency (EUDA). The agency’s latest report highlights a worrying trend in the availability and potency of illicit substances across 27 EU member states, along with Turkey and Norway. As the drug landscape evolves, so do the health challenges faced by users, with synthetic compounds and hybrid products posing new threats. The report calls for coordinated action to address these emerging dangers, which are compounded by the market’s growing diversity and sophistication.
Escalating Threats from Synthetic Opioids
Synthetic opioids have emerged as one of the most lethal substances in Europe’s drug market, according to EUDA. Lorraine Nolan, the agency’s Executive Director, warned that these drugs are significantly more potent than traditional opioids, with one gram capable of delivering thousands of lethal doses. “The margin between safe use and overdose is extremely narrow,” she said, emphasizing the need for improved user education and monitoring systems. The report notes that opioid-related deaths reached over 7,600 in the EU alone during 2024, with many incidents involving the mixing of drugs or unknown additives.
“New synthetic opioids are highly potent substances. One gram can produce several thousand lethal doses, making it easier for users to exceed safe thresholds unintentionally,” said Nolan. “This complexity in drug composition is increasing the risk of severe health consequences, including respiratory failure and cardiac arrest.”
Rise in New Psychoactive Substances
The drug market in Europe is also witnessing a rapid influx of new psychoactive substances (NPS), with at least one novel compound identified weekly. In 2025 alone, 50 such substances were detected, underscoring the difficulty in keeping up with the pace of innovation. EUDA currently tracks approximately 1,050 different compounds, including both traditional illicit drugs and cutting-edge synthetic alternatives. This proliferation of substances has led to a surge in cases of unknown toxicity and overdose, particularly among younger users who may be drawn to these drugs due to their novelty and lower price points.
While cannabis remains the most commonly used illicit drug in Europe, with 24.9 million adults reporting usage in the past year, its market is undergoing significant changes. High-potency cannabis products, often imported from North America, are now dominating the region, contributing to a rise in cannabis-related health issues such as psychosis and dependency. EUDA’s findings reveal that the availability of these potent forms is creating new risks for both recreational and medicinal users.
Global Trends and Local Impacts
The complexities of Europe’s drug market are part of a broader global shift. International trafficking networks are adapting to demand, leading to the widespread distribution of substances like fentanyl, methamphetamine, and designer stimulants. These trends are not only affecting urban centers but are also reaching rural and remote areas, where access to treatment and harm reduction services is limited. The EUDA report emphasizes that the consequences of this market expansion are far-reaching, with health risks increasingly linked to the increasing availability of potent and unpredictable drug combinations.
Additionally, the report points to the growing role of technology in drug distribution. Online platforms and encrypted messaging apps are facilitating the sale of illicit substances, often without clear labeling or quality control. This has resulted in a rise in cases where users are unaware of the exact composition of their drugs, heightening the likelihood of adverse reactions and overdose. The agency stresses that these developments are exacerbating existing challenges and creating new ones that require a multifaceted response.
Cocaine Seizures and Persistent Health Concerns
Despite a decline in cocaine seizures to 330 tonnes in 2024—down from 419 tonnes in 2023—the drug remains a major contributor to health crises in Europe. It accounts for a third of all individuals entering treatment programs, with its impact growing as higher-purity forms become more accessible. Nolan highlighted that some resin-based cocaine products now contain up to 33% impurities, increasing the risk of acute toxicity and long-term health complications. Contamination from synthetic cannabinoids and harmful pesticides further compounds these dangers, particularly among users who may not have access to laboratory-tested products.
Call for Strategic Action and Collaboration
With the drug market in Europe becoming more complex, the EUDA is urging member states to take strategic action to mitigate health risks. This includes investing in enhanced monitoring systems, expanding harm reduction programs, and improving public awareness of the dangers associated with emerging substances. The agency advocates for a balanced approach that addresses both supply and demand, emphasizing the importance of integrating public health and human rights principles into policy decisions. Nolan stressed that collaboration between national authorities and international partners is essential to combat the spread of new and potent drugs effectively.
